Target Gene/Pathway Pathway / Gene


Search results


No. KEGG GENES KEGG PATHWAY KEGG DRUG DrugBank 指定難病告示番号
1 SIGMAR1 2件: Amyotrophic lateral sclerosis, Pathways of neurodegeneration - multiple diseases D03742 Dextromethorphan 11件: 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
2 CD52 - D02802 Alemtuzumab 22件: 13, 15, 19, 20, 36, 43, 44, 46, 49, 51, 60, 62, 63, 65, 85, 96, 164, 234, 283, 284, 285, 326
3 TNFSF13B 4件: Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Intestinal immune network for IgA production, Rheumatoid arthritis D03068 Belimumab 13件: 11, 13, 43, 44, 46, 49, 51, 53, 63, 66, 222, 296, 300
4 TNFSF13B 4件: Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Intestinal immune network for IgA production, Rheumatoid arthritis D09704 Atacicept 4件: 13, 46, 49, 66
5 CYSLTR1 2件: Calcium signaling pathway, Neuroactive ligand-receptor interaction D01385 Ibudilast 2件: 2, 13
6 CYSLTR1 2件: Calcium signaling pathway, Neuroactive ligand-receptor interaction D08229 Montelukast 8件: 6, 13, 46, 61, 63, 85, 98, 228
7 CA5B 2件: Nitrogen metabolism, Metabolic pathways D00218 Acetazolamide 8件: 13, 86, 90, 115, 154, 155, 225, 230
8 CHRM1 8件: Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D00465 Oxybutynin 3件: 6, 13, 53
9 CHRM2 6件: Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton D00465 Oxybutynin 3件: 6, 13, 53
10 CHRM3 11件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D00465 Oxybutynin 3件: 6, 13, 53
11 CHRM3 11件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D03654 Darifenacin 2件: 6, 13
12 CHRM3 11件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D08522 Solifenacin 3件: 6, 13, 53
13 CHRM4 3件: Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton D00465 Oxybutynin 3件: 6, 13, 53
14 CHRM5 6件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D00465 Oxybutynin 3件: 6, 13, 53
15 CHRNA1 2件: Virion - Lyssavirus, Neuroactive ligand-receptor interaction D03365 Nicotine 3件: 6, 13, 84
16 CHRNA2 1件: Neuroactive ligand-receptor interaction D03365 Nicotine 2件: 13, 84
17 CHRNA3 3件: Neuroactive ligand-receptor interaction, Cholinergic synapse, Chemical carcinogenesis - receptor activation D03365 Nicotine 3件: 6, 13, 84
18 CHRNA4 4件: Neuroactive ligand-receptor interaction, Cholinergic synapse, Nicotine addiction, Chemical carcinogenesis - receptor activation D03365 Nicotine 3件: 6, 13, 84
19 CHRNA5 1件: Neuroactive ligand-receptor interaction D03365 Nicotine 2件: 13, 84
20 CHRNA7 7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Chemical carcinogenesis - receptor activation D03365 Nicotine 3件: 6, 13, 84
21 CHRNB1 1件: Neuroactive ligand-receptor interaction D03365 Nicotine 2件: 13, 84
22 CHRNB2 4件: Neuroactive ligand-receptor interaction, Cholinergic synapse, Nicotine addiction, Chemical carcinogenesis - receptor activation D03365 Nicotine 3件: 6, 13, 84
23 CHRNB3 1件: Neuroactive ligand-receptor interaction D03365 Nicotine 2件: 13, 84
24 CHRNB4 3件: Neuroactive ligand-receptor interaction, Cholinergic synapse, Chemical carcinogenesis - receptor activation D03365 Nicotine 3件: 6, 13, 84
25 CHRND 1件: Neuroactive ligand-receptor interaction D03365 Nicotine 2件: 13, 84
26 CHRNE 1件: Neuroactive ligand-receptor interaction D03365 Nicotine 2件: 13, 84
27 CHRNG 1件: Neuroactive ligand-receptor interaction D03365 Nicotine 2件: 13, 84
28 CLCN2 1件: Mineral absorption D04790 Lubiprostone 3件: 13, 290, 299
29 CNR1 4件: Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Retrograde endocannabinoid signaling D00306 Dronabinol 8件: 2, 8, 13, 36, 46, 96, 271, 298
30 CNR1 4件: Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Retrograde endocannabinoid signaling D05099 Nabilone 3件: 6, 13, 127
31 CNR1 4件: Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Retrograde endocannabinoid signaling D10915 Cannabidiol 20件: 2, 6, 8, 13, 36, 46, 51, 95, 96, 97, 140, 144, 145, 156, 157, 158, 193, 206, 226, 271
32 CNR2 1件: Neuroactive ligand-receptor interaction D00306 Dronabinol 6件: 13, 36, 46, 96, 271, 298
33 CNR2 1件: Neuroactive ligand-receptor interaction D05099 Nabilone 2件: 13, 127
34 CNR2 1件: Neuroactive ligand-receptor interaction D10915 Cannabidiol 17件: 13, 36, 46, 51, 95, 96, 97, 140, 144, 145, 156, 157, 158, 193, 206, 226, 271
35 ADORA1 7件: cGMP-PKG signaling pathway, cAMP signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D00045 Adenosine 3件: 13, 58, 65
36 ADORA2A 7件: Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease, Alcoholism D00045 Adenosine 3件: 13, 58, 65
37 ADORA2B 5件: Rap1 signaling pathway, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Alcoholism D00045 Adenosine 3件: 13, 58, 65
38 ADORA3 3件: cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D00045 Adenosine 3件: 13, 58, 65
39 CSF3R 5件: Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Pathways in cancer D03235 Filgrastim 35件: 2, 6, 11, 13, 16, 22, 25, 26, 28, 34, 35, 36, 38, 40, 41, 42, 45, 46, 47, 49, 51, 57, 60, 62, 65, 85, 96, 113, 164, 256, 283, 284, 285, 296, 331
40 CSF3R 5件: Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Pathways in cancer D03247 Lenograstim 7件: 2, 13, 16, 18, 19, 57, 65
41 ADRA1D 6件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D08560 Tamsulosin 1件: 13
42 ADRA1B 6件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D08560 Tamsulosin 1件: 13
43 ADRA1A 7件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D01965 Silodosin 2件: 6, 13
44 ADRA1A 7件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D07124 Alfuzosin 1件: 13
45 ADRA1A 7件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D08560 Tamsulosin 1件: 13
46 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D04375 Guanabenz 2件: 2, 13
47 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D07540 Brimonidine 2件: 13, 90
48 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08611 Tizanidine 1件: 13
49 ADRA2B 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D04375 Guanabenz 2件: 2, 13
50 ADRA2B 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D07540 Brimonidine 2件: 13, 90
51 ADRA2B 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08611 Tizanidine 1件: 13
52 ADRA2C 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D04375 Guanabenz 2件: 2, 13
53 ADRA2C 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D07540 Brimonidine 2件: 13, 90
54 ADRA2C 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08611 Tizanidine 1件: 13
55 ADRB2 9件: Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D02147 Salbutamol 12件: 3, 11, 12, 13, 49, 85, 86, 89, 111, 113, 256, 299
56 ADRB2 9件: Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D07713 Clenbuterol 5件: 1, 2, 6, 13, 256
57 ADRB2 9件: Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D08092 Isoxsuprine 1件: 13
58 ADRB3 8件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D09535 Mirabegron 4件: 6, 13, 53, 226
59 CYP17A1 6件: Steroid hormone biosynthesis, Metabolic pathways, Ovarian steroidogenesis, Prolactin signaling pathway, Cortisol synthesis and secretion, Cushing syndrome D00351 Ketoconazole 3件: 8, 13, 75
60 DDC 9件: Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Cocaine addiction, Amphetamine addiction, Alcoholism D00558 Carbidopa 7件: 6, 13, 17, 90, 140, 164, 201
61 DHFR 5件: One carbon pool by folate, Folate biosynthesis, Metabolic pathways, Biosynthesis of cofactors, Antifolate resistance D00142 Methotrexate 38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331
62 DHODH 3件: Pyrimidine metabolism, Metabolic pathways, Biosynthesis of cofactors D10172 Teriflunomide 3件: 13, 25, 26
63 NQO1 7件: Ubiquinone and other terpenoid-quinone biosynthesis, Metabolic pathways, Biosynthesis of cofactors, Pathways in cancer, Chemical carcinogenesis - reactive oxygen species, Hepatocellular carcinoma, Fluid shear stress and atherosclerosis D08682 Warfarin 11件: 6, 8, 13, 19, 46, 49, 66, 85, 86, 88, 91
64 DNMT1 3件: Cysteine and methionine metabolism, Metabolic pathways, MicroRNAs in cancer D03665 Decitabine 3件: 13, 60, 63
65 DNMT3A 3件: Cysteine and methionine metabolism, Metabolic pathways, MicroRNAs in cancer D03665 Decitabine 3件: 13, 60, 63
66 DNMT3B 3件: Cysteine and methionine metabolism, Metabolic pathways, MicroRNAs in cancer D03665 Decitabine 3件: 13, 60, 63
67 DRD2 8件: Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D01745 Domperidone 5件: 6, 13, 17, 51, 230
68 DRD2 8件: Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D07868 Domperidone 5件: 6, 13, 17, 51, 230
69 DRD2 8件: Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D08456 Quetiapine 2件: 6, 13
70 ABAT 7件: Alanine, aspartate and glutamate metabolism, Valine, leucine and isoleucine degradation, beta-Alanine metabolism, Propanoate metabolism, Butanoate metabolism, Metabolic pathways, GABAergic synapse D00399 Valproic acid 14件: 2, 3, 5, 6, 13, 26, 65, 85, 90, 102, 127, 222, 233, 256
71 S1PR1 3件: FoxO signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D10001 Fingolimod 3件: 13, 14, 156
72 S1PR1 3件: FoxO signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D10968 Ozanimod 3件: 13, 96, 97
73 S1PR1 3件: FoxO signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D11215 Ponesimod 1件: 13
74 S1PR1 3件: FoxO signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D11460 Siponimod 2件: 13, 50
75 S1PR3 2件: Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D10968 Ozanimod 3件: 13, 96, 97
76 ELANE 3件: Neutrophil extracellular trap formation, Transcriptional misregulation in cancer, Systemic lupus erythematosus D03788 Sivelestat 3件: 13, 85, 96
77 DHFR2 5件: One carbon pool by folate, Folate biosynthesis, Metabolic pathways, Biosynthesis of cofactors, Antifolate resistance D00142 Methotrexate 38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331
78 ESR1 9件: Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D00105 Estradiol 7件: 13, 46, 49, 65, 76, 226, 299
79 ESR1 9件: Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D00185 Estriol 2件: 13, 227
80 ESR1 9件: Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D00554 Ethinylestradiol 4件: 13, 46, 49, 299
81 ESR1 9件: Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D01986 Estriol 2件: 13, 227
82 ESR2 7件: Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D00105 Estradiol 7件: 13, 46, 49, 65, 76, 226, 299
83 ESR2 7件: Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D00185 Estriol 2件: 13, 227
84 ESR2 7件: Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D01986 Estriol 2件: 13, 227
85 FDPS 4件: Terpenoid backbone biosynthesis, Metabolic pathways, Influenza A, Human T-cell leukemia virus 1 infection D01968 Zoledronic acid 13件: 5, 6, 13, 17, 46, 65, 93, 95, 96, 270, 274, 299, 333
86 FDPS 4件: Terpenoid backbone biosynthesis, Metabolic pathways, Influenza A, Human T-cell leukemia virus 1 infection D08689 Zoledronic acid 13件: 5, 6, 13, 17, 46, 65, 93, 95, 96, 270, 274, 299, 333
87 FGFR2 13件: EGFR tyrosine kinase inhibitor resistance, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, Endocytosis, PI3K-Akt signaling pathway, Signaling pathways regulating pluripotency of stem cells, Regulation of actin cytoskeleton, Pathways in cancer, Prostate cancer, Gastric cancer, Central carbon metabolism in cancer D05338 Palifermin 5件: 13, 36, 38, 39, 65
88 NCSTN 2件: Notch signaling pathway, Alzheimer disease D09010 Tarenflurbil 1件: 13
89 CA14 2件: Nitrogen metabolism, Metabolic pathways D00218 Acetazolamide 8件: 13, 86, 90, 115, 154, 155, 225, 230
90 MTOR 51件: EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, HIF-1 signaling pathway, Phospholipase D signaling pathway, Autophagy - other, Autophagy - animal, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Cellular senescence, Apelin signaling pathway, Neutrophil extracellular trap formation, JAK-STAT signaling pathway, Th17 cell differentiation, Thermogenesis, Insulin signaling pathway, Thyroid hormone signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Growth hormone synthesis, secretion and action, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Shigellosis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Colorectal cancer, Pancreatic cancer, Glioma, Prostate cancer, Acute myeloid leukemia, Breast cancer, Hepatocellular carcinoma, Gastric cancer, Central carbon metabolism in cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Diabetic cardiomyopathy D00753 Sirolimus 40件: 2, 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331
91 MTOR 51件: EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, HIF-1 signaling pathway, Phospholipase D signaling pathway, Autophagy - other, Autophagy - animal, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Cellular senescence, Apelin signaling pathway, Neutrophil extracellular trap formation, JAK-STAT signaling pathway, Th17 cell differentiation, Thermogenesis, Insulin signaling pathway, Thyroid hormone signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Growth hormone synthesis, secretion and action, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Shigellosis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Colorectal cancer, Pancreatic cancer, Glioma, Prostate cancer, Acute myeloid leukemia, Breast cancer, Hepatocellular carcinoma, Gastric cancer, Central carbon metabolism in cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Diabetic cardiomyopathy D06068 Temsirolimus 1件: 13
92 GABBR1 7件: cAMP signaling pathway, Neuroactive ligand-receptor interaction, GABAergic synapse, Taste transduction, Estrogen signaling pathway, GnRH secretion, Morphine addiction D00241 Baclofen 8件: 2, 10, 13, 18, 65, 70, 149, 206
93 GABBR1 7件: cAMP signaling pathway, Neuroactive ligand-receptor interaction, GABAergic synapse, Taste transduction, Estrogen signaling pathway, GnRH secretion, Morphine addiction D08861 Arbaclofen Placarbil 1件: 13
94 GABBR1 7件: cAMP signaling pathway, Neuroactive ligand-receptor interaction, GABAergic synapse, Taste transduction, Estrogen signaling pathway, GnRH secretion, Morphine addiction D09791 Arbaclofen 2件: 13, 206
95 GABRA1 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299
96 GABRA1 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00697 Flumazenil 5件: 6, 13, 17, 18, 206
97 GABRA1 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D02624 Eszopiclone 3件: 6, 13, 46
98 GABRA2 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299
99 GABRA2 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00697 Flumazenil 5件: 6, 13, 17, 18, 206
100 GABRA2 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D02624 Eszopiclone 3件: 6, 13, 46
101 GABRA3 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299
102 GABRA3 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00697 Flumazenil 5件: 6, 13, 17, 18, 206
103 GABRA3 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D02624 Eszopiclone 3件: 6, 13, 46
104 GABRA4 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299
105 GABRA4 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00697 Flumazenil 5件: 6, 13, 17, 18, 206
106 GABRA4 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D02624 Eszopiclone 3件: 6, 13, 46
107 GABRA5 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299
108 GABRA5 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00697 Flumazenil 5件: 6, 13, 17, 18, 206
109 GABRA5 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D02624 Eszopiclone 3件: 6, 13, 46
110 GABRA6 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299
111 GABRA6 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00697 Flumazenil 5件: 6, 13, 17, 18, 206
112 GABRA6 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D02624 Eszopiclone 3件: 6, 13, 46
113 GABRB1 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299
114 GABRB1 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00697 Flumazenil 5件: 6, 13, 17, 18, 206
115 GABRB1 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D02624 Eszopiclone 3件: 6, 13, 46
116 GABRB2 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299
117 GABRB2 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00697 Flumazenil 5件: 6, 13, 17, 18, 206
118 GABRB2 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D02624 Eszopiclone 3件: 6, 13, 46
119 GABRB3 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299
120 GABRB3 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00697 Flumazenil 5件: 6, 13, 17, 18, 206
121 GABRB3 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D02624 Eszopiclone 3件: 6, 13, 46
122 GABRD 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299
123 GABRD 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00697 Flumazenil 5件: 6, 13, 17, 18, 206
124 GABRD 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D02624 Eszopiclone 3件: 6, 13, 46
125 GABRE 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299
126 GABRE 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00697 Flumazenil 5件: 6, 13, 17, 18, 206
127 GABRE 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D02624 Eszopiclone 3件: 6, 13, 46
128 GABRG1 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299
129 GABRG1 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00697 Flumazenil 5件: 6, 13, 17, 18, 206
130 GABRG1 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D02624 Eszopiclone 3件: 6, 13, 46
131 GABRG2 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299
132 GABRG2 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00697 Flumazenil 5件: 6, 13, 17, 18, 206
133 GABRG2 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D02624 Eszopiclone 3件: 6, 13, 46
134 GABRG3 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299
135 GABRG3 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00697 Flumazenil 5件: 6, 13, 17, 18, 206
136 GABRG3 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D02624 Eszopiclone 3件: 6, 13, 46
137 GABRP 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299
138 GABRP 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00697 Flumazenil 5件: 6, 13, 17, 18, 206
139 GABRP 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D02624 Eszopiclone 3件: 6, 13, 46
140 GAD1 7件: Alanine, aspartate and glutamate metabolism, beta-Alanine metabolism, Taurine and hypotaurine metabolism, Butanoate metabolism, Metabolic pathways, GABAergic synapse, Type I diabetes mellitus D00399 Valproic acid 14件: 2, 3, 5, 6, 13, 26, 65, 85, 90, 102, 127, 222, 233, 256
141 GAD2 7件: Alanine, aspartate and glutamate metabolism, beta-Alanine metabolism, Taurine and hypotaurine metabolism, Butanoate metabolism, Metabolic pathways, GABAergic synapse, Type I diabetes mellitus D00399 Valproic acid 14件: 2, 3, 5, 6, 13, 26, 65, 85, 90, 102, 127, 222, 233, 256
142 ABL1 11件: ErbB signaling pathway, Ras signaling pathway, Cell cycle, Axon guidance, Neurotrophin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, MicroRNAs in cancer, Chemical carcinogenesis - reactive oxygen species, Chronic myeloid leukemia, Viral myocarditis D08066 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162
143 GHRHR 2件: Neuroactive ligand-receptor interaction, Growth hormone synthesis, secretion and action D08523 Somatorelin 2件: 13, 78
144 GLP1R 3件: cAMP signaling pathway, Neuroactive ligand-receptor interaction, Insulin secretion D09889 Dulaglutide 2件: 13, 299
145 GRIA1 14件: cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Nicotine addiction D00775 Riluzole 9件: 2, 3, 5, 8, 13, 17, 18, 203, 206
146 GRIA2 15件: cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction D00775 Riluzole 9件: 2, 3, 5, 8, 13, 17, 18, 203, 206
147 GRIA3 13件: cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Nicotine addiction, Transcriptional misregulation in cancer D00775 Riluzole 9件: 2, 3, 5, 8, 13, 17, 18, 203, 206
148 GRIA4 10件: cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Nicotine addiction D00775 Riluzole 9件: 2, 3, 5, 8, 13, 17, 18, 203, 206
149 GRIK1 2件: Neuroactive ligand-receptor interaction, Glutamatergic synapse D00775 Riluzole 9件: 2, 3, 5, 8, 13, 17, 18, 203, 206
150 GRIK2 2件: Neuroactive ligand-receptor interaction, Glutamatergic synapse D00775 Riluzole 9件: 2, 3, 5, 8, 13, 17, 18, 203, 206
151 GRIK3 2件: Neuroactive ligand-receptor interaction, Glutamatergic synapse D00775 Riluzole 9件: 2, 3, 5, 8, 13, 17, 18, 203, 206
152 GRIK4 2件: Neuroactive ligand-receptor interaction, Glutamatergic synapse D00775 Riluzole 9件: 2, 3, 5, 8, 13, 17, 18, 203, 206
153 GRIK5 2件: Neuroactive ligand-receptor interaction, Glutamatergic synapse D00775 Riluzole 9件: 2, 3, 5, 8, 13, 17, 18, 203, 206
154 GRIN1 18件: Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D00775 Riluzole 9件: 2, 3, 5, 8, 13, 17, 18, 203, 206
155 GRIN1 18件: Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D03742 Dextromethorphan 11件: 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
156 GRIN1 18件: Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D07441 Amantadine 4件: 6, 8, 13, 127
157 GRIN1 18件: Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D08098 Ketamine 8件: 2, 4, 6, 13, 70, 113, 156, 215
158 GRIN1 18件: Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D08174 Memantine 8件: 2, 6, 8, 13, 49, 127, 205, 206
159 GRIN2A 19件: Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D00775 Riluzole 9件: 2, 3, 5, 8, 13, 17, 18, 203, 206
160 GRIN2A 19件: Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D03742 Dextromethorphan 11件: 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
161 GRIN2A 19件: Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D07441 Amantadine 4件: 6, 8, 13, 127
162 GRIN2A 19件: Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D08098 Ketamine 8件: 2, 4, 6, 13, 70, 113, 156, 215
163 GRIN2A 19件: Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D08174 Memantine 8件: 2, 6, 8, 13, 49, 127, 205, 206
164 GRIN2B 19件: Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D00775 Riluzole 9件: 2, 3, 5, 8, 13, 17, 18, 203, 206
165 GRIN2B 19件: Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D03742 Dextromethorphan 11件: 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
166 GRIN2B 19件: Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D07441 Amantadine 4件: 6, 8, 13, 127
167 GRIN2B 19件: Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D08098 Ketamine 8件: 2, 4, 6, 13, 70, 113, 156, 215
168 GRIN2B 19件: Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D08174 Memantine 8件: 2, 6, 8, 13, 49, 127, 205, 206
169 GRIN2C 15件: Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D00775 Riluzole 9件: 2, 3, 5, 8, 13, 17, 18, 203, 206
170 GRIN2C 15件: Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D03742 Dextromethorphan 11件: 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
171 GRIN2C 15件: Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D07441 Amantadine 4件: 6, 8, 13, 127
172 GRIN2C 15件: Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D08098 Ketamine 8件: 2, 4, 6, 13, 70, 113, 156, 215
173 GRIN2C 15件: Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D08174 Memantine 8件: 2, 6, 8, 13, 49, 127, 205, 206
174 GRIN2D 15件: Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D00775 Riluzole 9件: 2, 3, 5, 8, 13, 17, 18, 203, 206
175 GRIN2D 15件: Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D03742 Dextromethorphan 11件: 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
176 GRIN2D 15件: Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D07441 Amantadine 4件: 6, 8, 13, 127
177 GRIN2D 15件: Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D08098 Ketamine 8件: 2, 4, 6, 13, 70, 113, 156, 215
178 GRIN2D 15件: Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D08174 Memantine 8件: 2, 6, 8, 13, 49, 127, 205, 206
179 NR3C1 1件: Neuroactive ligand-receptor interaction D00292 Dexamethasone 22件: 13, 14, 16, 28, 35, 46, 53, 63, 64, 65, 70, 81, 84, 96, 97, 162, 222, 235, 257, 283, 296, 299
180 NR3C1 1件: Neuroactive ligand-receptor interaction D00407 Methylprednisolone 44件: 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 85, 86, 93, 95, 96, 97, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296
181 NR3C1 1件: Neuroactive ligand-receptor interaction D00472 Prednisolone 40件: 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300
182 NR3C1 1件: Neuroactive ligand-receptor interaction D00473 Prednisone 43件: 13, 14, 19, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 79, 81, 84, 85, 86, 95, 96, 97, 113, 162, 164, 205, 222, 224, 228, 283, 284, 288, 299, 300, 307, 331
183 NR3C1 1件: Neuroactive ligand-receptor interaction D05000 Methylprednisolone hemisuccinate 7件: 13, 49, 50, 51, 53, 97, 211
184 HCRTR1 1件: Neuroactive ligand-receptor interaction D10082 Suvorexant 1件: 13
185 HCRTR2 1件: Neuroactive ligand-receptor interaction D10082 Suvorexant 1件: 13
186 HMGCR 4件: Terpenoid backbone biosynthesis, Metabolic pathways, AMPK signaling pathway, Bile secretion D00434 Simvastatin 21件: 6, 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 160, 162, 195, 265, 288, 298, 299, 310
187 HMGCR 4件: Terpenoid backbone biosynthesis, Metabolic pathways, AMPK signaling pathway, Bile secretion D07474 Atorvastatin 19件: 13, 46, 49, 51, 58, 63, 79, 84, 88, 93, 96, 97, 160, 222, 225, 265, 271, 297, 299
188 HMGCR 4件: Terpenoid backbone biosynthesis, Metabolic pathways, AMPK signaling pathway, Bile secretion D08410 Pravastatin 9件: 13, 46, 49, 67, 79, 96, 164, 265, 333
189 HPRT1 4件: Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism D08603 Tioguanine 2件: 13, 37
190 HRH1 3件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels D00300 Diphenhydramine 8件: 11, 13, 49, 51, 70, 86, 222, 256
191 HRH1 3件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels D00364 Loratadine 4件: 13, 46, 89, 98
192 HRH1 3件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels D03535 Clemastine 1件: 13
193 HRH1 3件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels D03693 Desloratadine 1件: 13
194 HRH1 3件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels D07662 Cetirizine 4件: 13, 28, 35, 300
195 HRH1 3件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels D07803 Dexchlorpheniramine 2件: 13, 49
196 HRH1 3件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels D07958 Fexofenadine 2件: 13, 46
197 HRH2 3件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gastric acid secretion D00422 Ranitidine 2件: 13, 65
198 HTR2A 5件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels D00274 Cisapride 1件: 13
199 HTR2A 5件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels D02092 Cisapride 1件: 13
200 HTR2A 5件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels D08456 Quetiapine 2件: 6, 13
201 HTR3A 2件: Serotonergic synapse, Taste transduction D00274 Cisapride 1件: 13
202 HTR3A 2件: Serotonergic synapse, Taste transduction D02092 Cisapride 1件: 13
203 HTR4 4件: Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Serotonergic synapse D00274 Cisapride 1件: 13
204 HTR4 4件: Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Serotonergic synapse D02092 Cisapride 1件: 13
205 HTR4 4件: Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Serotonergic synapse D09205 Prucalopride 3件: 13, 51, 96
206 IFNAR1 18件: Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Hepatitis B, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer D00746 Interferon beta-1b 1件: 13
207 IFNAR1 18件: Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Hepatitis B, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer D03305 Interferon alfa 6件: 13, 25, 26, 28, 56, 96
208 IFNAR1 18件: Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Hepatitis B, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer D04554 Interferon beta-1a 4件: 13, 26, 96, 97
209 IFNAR1 18件: Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Hepatitis B, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer D10483 Peginterferon beta-1a 1件: 13
210 IFNAR2 17件: Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer D00746 Interferon beta-1b 1件: 13
211 IFNAR2 17件: Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer D03305 Interferon alfa 6件: 13, 25, 26, 28, 56, 96
212 IFNAR2 17件: Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer D04554 Interferon beta-1a 4件: 13, 26, 96, 97
213 IFNAR2 17件: Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer D10483 Peginterferon beta-1a 1件: 13
214 IL1A 21件: MAPK signaling pathway, Cytokine-cytokine receptor interaction, Necroptosis, Cellular senescence, Osteoclast differentiation, Hematopoietic cell lineage, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Type I diabetes mellitus, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pertussis, Leishmaniasis, Tuberculosis, Measles, Influenza A, Inflammatory bowel disease, Rheumatoid arthritis, Graft-versus-host disease, Fluid shear stress and atherosclerosis D01583 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228
215 IL1B 44件: Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Cytosolic DNA-sensing pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th17 cell differentiation, TNF signaling pathway, Inflammatory mediator regulation of TRP channels, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Amoebiasis, Tuberculosis, Measles, Human cytomegalovirus infection, Influenza A, Herpes simplex virus 1 infection, Coronavirus disease - COVID-19, Inflammatory bowel disease, Rheumatoid arthritis, Graft-versus-host disease, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D01583 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228
216 IL1R1 13件: MAPK signaling pathway, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Osteoclast differentiation, Hematopoietic cell lineage, Th17 cell differentiation, Inflammatory mediator regulation of TRP channels, Pathogenic Escherichia coli infection, Shigellosis, Amoebiasis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Fluid shear stress and atherosclerosis D02934 Anakinra 18件: 2, 13, 15, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299
217 IL2RA 11件: Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, Endocytosis, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, Measles, Human T-cell leukemia virus 1 infection, Pathways in cancer D03639 Daclizumab 8件: 13, 56, 60, 65, 97, 107, 283, 284
218 IL6 51件: EGFR tyrosine kinase inhibitor resistance, Antifolate resistance, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, HIF-1 signaling pathway, FoxO signaling pathway, PI3K-Akt signaling pathway, Cellular senescence, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Cytosolic DNA-sensing pathway, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th17 cell differentiation, TNF signaling pathway, Intestinal immune network for IgA production, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Chagas disease, African trypanosomiasis, Malaria, Amoebiasis, Tuberculosis, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer, Transcriptional misregulation in cancer, Inflammatory bowel disease, Rheumatoid arthritis, Graft-versus-host disease, Hypertrophic cardiomyopathy, Lipid and atherosclerosis D01583 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228
219 IL6R 12件: EGFR tyrosine kinase inhibitor resistance, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, HIF-1 signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Th17 cell differentiation, Non-alcoholic fatty liver disease, Human cytomegalovirus infection, Coronavirus disease - COVID-19, Pathways in cancer D02596 Tocilizumab 21件: 2, 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331
220 IL6R 12件: EGFR tyrosine kinase inhibitor resistance, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, HIF-1 signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Th17 cell differentiation, Non-alcoholic fatty liver disease, Human cytomegalovirus infection, Coronavirus disease - COVID-19, Pathways in cancer D11079 Satralizumab 3件: 11, 13, 86
221 IL10 22件: Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, FoxO signaling pathway, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, T cell receptor signaling pathway, Intestinal immune network for IgA production, Pertussis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Staphylococcus aureus infection, Tuberculosis, Asthma, Autoimmune thyroid disease, Inflammatory bowel disease, Systemic lupus erythematosus, Allograft rejection D01583 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228
222 IL17A 6件: Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Th17 cell differentiation, Alcoholic liver disease, Inflammatory bowel disease, Rheumatoid arthritis D09967 Secukinumab 8件: 13, 37, 41, 46, 107, 160, 269, 271
223 IMPDH1 4件: Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism D00752 Mycophenolate mofetil 34件: 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 85, 93, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300
224 IMPDH1 4件: Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism D05096 Mycophenolic acid 36件: 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 84, 85, 93, 95, 96, 162, 164, 222, 224, 226, 228, 234, 283, 284, 285, 300
225 IMPDH2 4件: Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism D00752 Mycophenolate mofetil 34件: 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 85, 93, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300
226 IMPDH2 4件: Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism D05096 Mycophenolic acid 36件: 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 84, 85, 93, 95, 96, 162, 164, 222, 224, 226, 228, 234, 283, 284, 285, 300
227 ITGA4 14件: PI3K-Akt signaling pathway, Focal adhesion, ECM-receptor interaction, Cell adhesion molecules, Hematopoietic cell lineage, Leukocyte transendothelial migration, Intestinal immune network for IgA production, Regulation of actin cytoskeleton, Yersinia infection, Leishmaniasis, Human papillomavirus infection, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy D06590 Firategrast 1件: 13
228 ITGA4 14件: PI3K-Akt signaling pathway, Focal adhesion, ECM-receptor interaction, Cell adhesion molecules, Hematopoietic cell lineage, Leukocyte transendothelial migration, Intestinal immune network for IgA production, Regulation of actin cytoskeleton, Yersinia infection, Leishmaniasis, Human papillomavirus infection, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy D06886 Natalizumab 6件: 13, 15, 25, 46, 63, 96
229 AR 4件: Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer D00075 Testosterone 8件: 1, 2, 3, 13, 60, 76, 78, 113
230 AR 4件: Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer D06087 Testosterone undecanoate 2件: 13, 60
231 ITGAL 12件: Rap1 signaling pathway, Cell adhesion molecules, Neutrophil extracellular trap formation, Natural killer cell mediated cytotoxicity, Leukocyte transendothelial migration, Regulation of actin cytoskeleton, Malaria, Staphylococcus aureus infection, Human T-cell leukemia virus 1 infection, Epstein-Barr virus infection, Rheumatoid arthritis, Viral myocarditis D03959 Efalizumab 9件: 11, 13, 37, 46, 49, 53, 61, 95, 96
232 KCNA4 2件: Cortisol synthesis and secretion, Cushing syndrome D04127 Dalfampridine 5件: 3, 4, 6, 13, 14
233 KCNC3 1件: Spinocerebellar ataxia D04127 Dalfampridine 2件: 13, 14
234 KCND2 1件: Serotonergic synapse D04127 Dalfampridine 2件: 13, 14
235 KCND3 1件: Spinocerebellar ataxia D04127 Dalfampridine 2件: 13, 14
236 KCNJ11 3件: Insulin secretion, GnRH secretion, Type II diabetes mellitus D00294 Diazoxide 2件: 13, 193
237 CA13 2件: Nitrogen metabolism, Metabolic pathways D00218 Acetazolamide 8件: 13, 86, 90, 115, 154, 155, 225, 230
238 KIT 11件: MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Hematopoietic cell lineage, Melanogenesis, Pathways in cancer, Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer D08066 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162
239 KIT 11件: MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Hematopoietic cell lineage, Melanogenesis, Pathways in cancer, Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer D10229 Masitinib 6件: 2, 5, 6, 13, 46, 96
240 LTB 3件: Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Rheumatoid arthritis D08866 Baminercept 4件: 13, 46, 53, 97
241 MC2R 5件: cAMP signaling pathway, Neuroactive ligand-receptor interaction, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome D00146 Corticotropin 12件: 2, 13, 14, 46, 49, 50, 66, 75, 81, 84, 145, 222
242 ACHE 2件: Glycerophospholipid metabolism, Cholinergic synapse D03822 Rivastigmine 3件: 5, 6, 13
243 ACHE 2件: Glycerophospholipid metabolism, Cholinergic synapse D07869 Donepezil 9件: 5, 6, 13, 46, 78, 124, 127, 156, 206
244 MTNR1A 2件: Neuroactive ligand-receptor interaction, Circadian entrainment D08170 Melatonin 12件: 6, 8, 13, 37, 46, 49, 72, 78, 90, 97, 145, 202
245 MTNR1B 2件: Neuroactive ligand-receptor interaction, Circadian entrainment D08170 Melatonin 12件: 6, 8, 13, 37, 46, 49, 72, 78, 90, 97, 145, 202
246 ATP4A 4件: Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D05353 Pantoprazole 2件: 13, 65
247 ATP4A 4件: Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D07917 Esomeprazole 8件: 13, 46, 86, 98, 107, 113, 298, 299
248 ATP4B 4件: Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D05353 Pantoprazole 2件: 13, 65
249 ATP4B 4件: Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D07917 Esomeprazole 8件: 13, 46, 86, 98, 107, 113, 298, 299
250 OPRD1 3件: cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D05113 Naltrexone 13件: 6, 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226
251 OPRD1 3件: cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D05312 Oxycodone 5件: 6, 13, 70, 226, 298
252 OPRD1 3件: cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D08144 Loperamide 2件: 13, 97
253 OPRK1 1件: Neuroactive ligand-receptor interaction D05113 Naltrexone 11件: 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226
254 OPRK1 1件: Neuroactive ligand-receptor interaction D05312 Oxycodone 4件: 13, 70, 226, 298
255 OPRK1 1件: Neuroactive ligand-receptor interaction D08144 Loperamide 2件: 13, 97
256 OPRM1 3件: Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction D05113 Naltrexone 13件: 6, 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226
257 OPRM1 3件: Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction D05312 Oxycodone 5件: 6, 13, 70, 226, 298
258 OPRM1 3件: Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction D08144 Loperamide 2件: 13, 97
259 APH1A 2件: Notch signaling pathway, Alzheimer disease D09010 Tarenflurbil 1件: 13
260 PDCD1 3件: Cell adhesion molecules, T cell receptor signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer D10316 Nivolumab 12件: 13, 26, 41, 46, 49, 50, 51, 53, 85, 96, 97, 159
261 PDE3A 6件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, cAMP signaling pathway, Renin secretion, Morphine addiction D01385 Ibudilast 2件: 2, 13
262 PDE3B 11件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, cAMP signaling pathway, Apelin signaling pathway, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Glucagon signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D01385 Ibudilast 2件: 2, 13
263 PDE4A 5件: Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D01385 Ibudilast 2件: 2, 13
264 PDE4A 5件: Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D01783 Rolipram 2件: 8, 13
265 PDE4B 5件: Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D01385 Ibudilast 2件: 2, 13
266 PDE4B 5件: Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D01783 Rolipram 2件: 8, 13
267 PDE4C 5件: Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D01385 Ibudilast 2件: 2, 13
268 PDE4C 5件: Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D01783 Rolipram 2件: 8, 13
269 PDE4D 5件: Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D01385 Ibudilast 2件: 2, 13
270 PDE4D 5件: Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D01783 Rolipram 2件: 8, 13
271 PDGFRA 20件: EGFR tyrosine kinase inhibitor resistance, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, Phospholipase D signaling pathway, Endocytosis, PI3K-Akt signaling pathway, Focal adhesion, Gap junction, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Human cytomegalovirus infection, Pathways in cancer, MicroRNAs in cancer, Glioma, Prostate cancer, Melanoma, Central carbon metabolism in cancer, Choline metabolism in cancer D08066 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162
272 PGR 5件: Oocyte meiosis, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Chemical carcinogenesis - receptor activation, Breast cancer D00182 Norethisterone 4件: 13, 46, 49, 299
273 PGR 5件: Oocyte meiosis, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Chemical carcinogenesis - receptor activation, Breast cancer D00950 Levonorgestrel 1件: 13
274 PGR 5件: Oocyte meiosis, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Chemical carcinogenesis - receptor activation, Breast cancer D00951 Medroxyprogesterone acetate 8件: 13, 35, 46, 49, 50, 51, 60, 107
275 PGR 5件: Oocyte meiosis, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Chemical carcinogenesis - receptor activation, Breast cancer D01217 Dydrogesterone 1件: 13
276 PGR 5件: Oocyte meiosis, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Chemical carcinogenesis - receptor activation, Breast cancer D07222 Nomegestrol 1件: 13
277 PGR 5件: Oocyte meiosis, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Chemical carcinogenesis - receptor activation, Breast cancer D08281 Nomegestrol acetate 1件: 13
278 S1PR5 2件: Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D10968 Ozanimod 3件: 13, 96, 97
279 S1PR5 2件: Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D11460 Siponimod 2件: 13, 50
280 PPARG 11件: PPAR signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Osteoclast differentiation, Thermogenesis, Non-alcoholic fatty liver disease, Huntington disease, Pathways in cancer, Transcriptional misregulation in cancer, Thyroid cancer, Lipid and atherosclerosis D08378 Pioglitazone 17件: 2, 6, 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299
281 PPP3CA 33件: MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00107 Tacrolimus 34件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
282 PPP3CA 33件: MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D08556 Tacrolimus 34件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
283 PPP3CB 33件: MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00107 Tacrolimus 34件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
284 PPP3CB 33件: MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D08556 Tacrolimus 34件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
285 PPP3CC 33件: MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00107 Tacrolimus 34件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
286 PPP3CC 33件: MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D08556 Tacrolimus 34件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
287 PPP3R1 32件: MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00107 Tacrolimus 34件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
288 PPP3R1 32件: MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D08556 Tacrolimus 34件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
289 PPP3R2 32件: MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00107 Tacrolimus 34件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
290 PPP3R2 32件: MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D08556 Tacrolimus 34件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
291 CHRNA9 2件: Neuroactive ligand-receptor interaction, Chemical carcinogenesis - receptor activation D03365 Nicotine 3件: 6, 13, 84
292 PRKAA1 20件: FoxO signaling pathway, Autophagy - animal, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Apelin signaling pathway, Tight junction, Circadian rhythm, Thermogenesis, Insulin signaling pathway, Adipocytokine signaling pathway, Oxytocin signaling pathway, Glucagon signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, Alcoholic liver disease, Hypertrophic cardiomyopathy, Fluid shear stress and atherosclerosis D04966 Metformin 25件: 2, 6, 8, 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 218, 225, 233, 265, 285, 299, 301
293 PRKAA2 20件: FoxO signaling pathway, Autophagy - animal, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Apelin signaling pathway, Tight junction, Circadian rhythm, Thermogenesis, Insulin signaling pathway, Adipocytokine signaling pathway, Oxytocin signaling pathway, Glucagon signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, Alcoholic liver disease, Hypertrophic cardiomyopathy, Fluid shear stress and atherosclerosis D04966 Metformin 25件: 2, 6, 8, 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 218, 225, 233, 265, 285, 299, 301
294 CACNA2D3 7件: MAPK signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Oxytocin signaling pathway, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy D00332 Gabapentin 5件: 6, 13, 19, 70, 298
295 CACNA2D3 7件: MAPK signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Oxytocin signaling pathway, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy D02716 Pregabalin 5件: 13, 36, 46, 70, 298
296 PSENEN 2件: Notch signaling pathway, Alzheimer disease D09010 Tarenflurbil 1件: 13
297 GABRQ 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299
298 GABRQ 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00697 Flumazenil 5件: 6, 13, 17, 18, 206
299 GABRQ 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D02624 Eszopiclone 3件: 6, 13, 46
300 PSEN1 6件: Wnt signaling pathway, Notch signaling pathway, Neurotrophin signaling pathway, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Human papillomavirus infection D09010 Tarenflurbil 1件: 13
301 PSMB5 8件: Proteasome, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases D03150 Bortezomib 17件: 11, 13, 26, 28, 46, 49, 51, 61, 63, 64, 66, 222, 228, 256, 283, 288, 331
302 PSMB5 8件: Proteasome, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases D10130 Ixazomib 5件: 13, 16, 28, 51, 61
303 RGMA 2件: TGF-beta signaling pathway, Axon guidance D11355 Elezanumab 1件: 13
304 CHRNA10 1件: Neuroactive ligand-receptor interaction D03365 Nicotine 2件: 13, 84
305 PTGDR 1件: Neuroactive ligand-receptor interaction D01128 Ramatroban 1件: 13
306 PTGIR 3件: Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Platelet activation D01385 Ibudilast 2件: 2, 13
307 PTGS1 5件: Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes D00109 Acetylsalicylic acid 14件: 13, 22, 46, 49, 51, 58, 64, 86, 97, 113, 158, 210, 231, 251
308 PTGS1 5件: Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes D00118 Naproxen 4件: 13, 46, 107, 271
309 PTGS1 5件: Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes D00126 Ibuprofen 7件: 13, 46, 65, 107, 113, 271, 299
310 PTGS1 5件: Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes D00217 Acetaminophen 15件: 3, 6, 11, 13, 34, 35, 46, 49, 51, 70, 86, 222, 256, 271, 337
311 PTGS1 5件: Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes D00330 Flurbiprofen 3件: 13, 21, 46
312 PTGS1 5件: Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes D07816 Diclofenac 5件: 13, 34, 46, 78, 271
313 PTGS2 22件: Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D00109 Acetylsalicylic acid 14件: 13, 22, 46, 49, 51, 58, 64, 86, 97, 113, 158, 210, 231, 251
314 PTGS2 22件: Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D00118 Naproxen 4件: 13, 46, 107, 271
315 PTGS2 22件: Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D00126 Ibuprofen 7件: 13, 46, 65, 107, 113, 271, 299
316 PTGS2 22件: Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D00217 Acetaminophen 15件: 3, 6, 11, 13, 34, 35, 46, 49, 51, 70, 86, 222, 256, 271, 337
317 PTGS2 22件: Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D00330 Flurbiprofen 3件: 13, 21, 46
318 PTGS2 22件: Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D07816 Diclofenac 5件: 13, 34, 46, 78, 271
319 RARA 5件: Th17 cell differentiation, Estrogen signaling pathway, Pathways in cancer, Transcriptional misregulation in cancer, Acute myeloid leukemia D06543 Vitamin A 3件: 13, 53, 90
320 RARB 4件: Pathways in cancer, Small cell lung cancer, Non-small cell lung cancer, Gastric cancer D06543 Vitamin A 3件: 13, 53, 90
321 RRM1 6件: Purine metabolism, Pyrimidine metabolism, Glutathione metabolism, Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism D01370 Cladribine 3件: 11, 13, 94
322 RRM1 6件: Purine metabolism, Pyrimidine metabolism, Glutathione metabolism, Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism D07966 Fludarabine 20件: 11, 13, 19, 28, 36, 46, 49, 51, 60, 61, 62, 65, 85, 96, 164, 283, 284, 285, 286, 326
323 RRM2 7件: Purine metabolism, Pyrimidine metabolism, Glutathione metabolism, Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, p53 signaling pathway D00341 Hydroxyurea 8件: 3, 13, 19, 20, 65, 85, 86, 284
324 RXRA 17件: PPAR signaling pathway, PI3K-Akt signaling pathway, Th17 cell differentiation, Thyroid hormone signaling pathway, Adipocytokine signaling pathway, Parathyroid hormone synthesis, secretion and action, Non-alcoholic fatty liver disease, Bile secretion, Hepatitis C, Pathways in cancer, Transcriptional misregulation in cancer, Chemical carcinogenesis - receptor activation, Thyroid cancer, Small cell lung cancer, Non-small cell lung cancer, Gastric cancer, Lipid and atherosclerosis D03106 Bexarotene 2件: 13, 75
325 RXRB 13件: PPAR signaling pathway, Th17 cell differentiation, Thyroid hormone signaling pathway, Adipocytokine signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Transcriptional misregulation in cancer, Chemical carcinogenesis - receptor activation, Thyroid cancer, Small cell lung cancer, Non-small cell lung cancer, Gastric cancer, Lipid and atherosclerosis D03106 Bexarotene 2件: 13, 75
326 RXRG 13件: PPAR signaling pathway, Th17 cell differentiation, Thyroid hormone signaling pathway, Adipocytokine signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Transcriptional misregulation in cancer, Chemical carcinogenesis - receptor activation, Thyroid cancer, Small cell lung cancer, Non-small cell lung cancer, Gastric cancer, Lipid and atherosclerosis D03106 Bexarotene 2件: 13, 75
327 SCN1A 1件: Dopaminergic synapse D00252 Carbamazepine 2件: 13, 231
328 SCN1A 1件: Dopaminergic synapse D00354 Lamotrigine 5件: 13, 34, 38, 114, 144
329 SCN1A 1件: Dopaminergic synapse D00358 Lidocaine 12件: 13, 22, 34, 46, 51, 70, 84, 86, 107, 168, 226, 256
330 SCN1A 1件: Dopaminergic synapse D00512 Phenytoin 1件: 13
331 SCN1A 1件: Dopaminergic synapse D00533 Oxcarbazepine 1件: 13
332 SCN1A 1件: Dopaminergic synapse D08127 Lidocaine 12件: 13, 22, 34, 46, 51, 70, 84, 86, 107, 168, 226, 256
333 SCN1A 1件: Dopaminergic synapse D08458 Quinidine 1件: 13
334 SCN2A 1件: Taste transduction D00252 Carbamazepine 2件: 13, 231
335 SCN2A 1件: Taste transduction D00354 Lamotrigine 5件: 13, 34, 38, 114, 144
336 SCN2A 1件: Taste transduction D00358 Lidocaine 12件: 13, 22, 34, 46, 51, 70, 84, 86, 107, 168, 226, 256
337 SCN2A 1件: Taste transduction D00512 Phenytoin 1件: 13
338 SCN2A 1件: Taste transduction D00533 Oxcarbazepine 1件: 13
339 SCN2A 1件: Taste transduction D08127 Lidocaine 12件: 13, 22, 34, 46, 51, 70, 84, 86, 107, 168, 226, 256
340 SCN2A 1件: Taste transduction D08458 Quinidine 1件: 13
341 SCN3A 1件: Taste transduction D00252 Carbamazepine 2件: 13, 231
342 SCN3A 1件: Taste transduction D00354 Lamotrigine 5件: 13, 34, 38, 114, 144
343 SCN3A 1件: Taste transduction D00358 Lidocaine 12件: 13, 22, 34, 46, 51, 70, 84, 86, 107, 168, 226, 256
344 SCN3A 1件: Taste transduction D00512 Phenytoin 1件: 13
345 SCN3A 1件: Taste transduction D00533 Oxcarbazepine 1件: 13
346 SCN3A 1件: Taste transduction D08127 Lidocaine 12件: 13, 22, 34, 46, 51, 70, 84, 86, 107, 168, 226, 256
347 SCN3A 1件: Taste transduction D08458 Quinidine 1件: 13
348 SCN5A 1件: Adrenergic signaling in cardiomyocytes D00252 Carbamazepine 2件: 13, 231
349 SCN5A 1件: Adrenergic signaling in cardiomyocytes D00354 Lamotrigine 5件: 13, 34, 38, 114, 144
350 SCN5A 1件: Adrenergic signaling in cardiomyocytes D00358 Lidocaine 12件: 13, 22, 34, 46, 51, 70, 84, 86, 107, 168, 226, 256
351 SCN5A 1件: Adrenergic signaling in cardiomyocytes D00512 Phenytoin 1件: 13
352 SCN5A 1件: Adrenergic signaling in cardiomyocytes D00533 Oxcarbazepine 1件: 13
353 SCN5A 1件: Adrenergic signaling in cardiomyocytes D08127 Lidocaine 12件: 13, 22, 34, 46, 51, 70, 84, 86, 107, 168, 226, 256
354 SCN5A 1件: Adrenergic signaling in cardiomyocytes D08458 Quinidine 1件: 13
355 SCN9A 1件: Taste transduction D00252 Carbamazepine 2件: 13, 231
356 SCN9A 1件: Taste transduction D00354 Lamotrigine 5件: 13, 34, 38, 114, 144
357 SCN9A 1件: Taste transduction D00358 Lidocaine 12件: 13, 22, 34, 46, 51, 70, 84, 86, 107, 168, 226, 256
358 SCN9A 1件: Taste transduction D00512 Phenytoin 1件: 13
359 SCN9A 1件: Taste transduction D00533 Oxcarbazepine 1件: 13
360 SCN9A 1件: Taste transduction D08127 Lidocaine 12件: 13, 22, 34, 46, 51, 70, 84, 86, 107, 168, 226, 256
361 SCN9A 1件: Taste transduction D08458 Quinidine 1件: 13
362 SCNN1A 2件: Taste transduction, Aldosterone-regulated sodium reabsorption D07447 Amiloride 4件: 13, 67, 225, 299
363 SCNN1B 2件: Taste transduction, Aldosterone-regulated sodium reabsorption D07447 Amiloride 4件: 13, 67, 225, 299
364 SCNN1G 2件: Taste transduction, Aldosterone-regulated sodium reabsorption D07447 Amiloride 4件: 13, 67, 225, 299
365 CCL2 17件: Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, Chemokine signaling pathway, NOD-like receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, AGE-RAGE signaling pathway in diabetic complications, Yersinia infection, Chagas disease, Malaria, Human cytomegalovirus infection, Influenza A, Herpes simplex virus 1 infection, Coronavirus disease - COVID-19, Rheumatoid arthritis, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D01583 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228
366 SLC6A1 2件: Synaptic vesicle cycle, GABAergic synapse D00332 Gabapentin 5件: 6, 13, 19, 70, 298
367 SLC6A2 1件: Synaptic vesicle cycle D04999 Methylphenidate 6件: 13, 34, 84, 113, 179, 206
368 SLC6A2 1件: Synaptic vesicle cycle D07473 Atomoxetine 2件: 13, 17
369 SLC6A2 1件: Synaptic vesicle cycle D07880 Duloxetine 1件: 13
370 SLC6A2 1件: Synaptic vesicle cycle D08130 Lisdexamfetamine 1件: 13
371 SLC6A2 1件: Synaptic vesicle cycle D08670 Venlafaxine 2件: 13, 46
372 SLC6A3 7件: Synaptic vesicle cycle, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Alcoholism D03215 Armodafinil 3件: 6, 13, 84
373 SLC6A3 7件: Synaptic vesicle cycle, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Alcoholism D04999 Methylphenidate 7件: 6, 13, 34, 84, 113, 179, 206
374 SLC6A3 7件: Synaptic vesicle cycle, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Alcoholism D08130 Lisdexamfetamine 1件: 13
375 SLC6A4 2件: Synaptic vesicle cycle, Serotonergic synapse D00326 Fluoxetine 6件: 13, 17, 78, 86, 179, 206
376 SLC6A4 2件: Synaptic vesicle cycle, Serotonergic synapse D02362 Paroxetine 4件: 6, 13, 46, 85
377 SLC6A4 2件: Synaptic vesicle cycle, Serotonergic synapse D07704 Citalopram 7件: 6, 8, 13, 18, 46, 98, 127
378 SLC6A4 2件: Synaptic vesicle cycle, Serotonergic synapse D07880 Duloxetine 2件: 6, 13
379 SLC6A4 2件: Synaptic vesicle cycle, Serotonergic synapse D07913 Escitalopram 4件: 2, 6, 13, 46
380 SLC6A4 2件: Synaptic vesicle cycle, Serotonergic synapse D08670 Venlafaxine 3件: 6, 13, 46
381 SLC12A3 - D00340 Hydrochlorothiazide 4件: 13, 67, 225, 235
382 SLC12A3 - D00345 Indapamide 1件: 13
383 SNAP25 2件: Synaptic vesicle cycle, Insulin secretion D00783 Botulinum toxin type A 14件: 2, 5, 6, 7, 13, 15, 17, 36, 47, 51, 70, 113, 149, 226
384 SNAP25 2件: Synaptic vesicle cycle, Insulin secretion D02735 Botulinum toxin type B 4件: 2, 6, 13, 51
385 ABCC8 3件: ABC transporters, Insulin secretion, Type II diabetes mellitus D00294 Diazoxide 2件: 13, 193
386 TBXA2R 3件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Platelet activation D01128 Ramatroban 1件: 13
387 BTK 7件: NF-kappa B signaling pathway, Osteoclast differentiation, Platelet activation, B cell receptor signaling pathway, Fc epsilon RI signaling pathway, Epstein-Barr virus infection, Primary immunodeficiency D11422 Zanubrutinib 5件: 13, 63, 222, 300, 331
388 BTK 7件: NF-kappa B signaling pathway, Osteoclast differentiation, Platelet activation, B cell receptor signaling pathway, Fc epsilon RI signaling pathway, Epstein-Barr virus infection, Primary immunodeficiency D11457 Fenebrutinib 1件: 13
389 BTK 7件: NF-kappa B signaling pathway, Osteoclast differentiation, Platelet activation, B cell receptor signaling pathway, Fc epsilon RI signaling pathway, Epstein-Barr virus infection, Primary immunodeficiency D12160 Orelabrutinib 4件: 13, 49, 61, 63
390 BTK 7件: NF-kappa B signaling pathway, Osteoclast differentiation, Platelet activation, B cell receptor signaling pathway, Fc epsilon RI signaling pathway, Epstein-Barr virus infection, Primary immunodeficiency D12285 Remibrutinib 2件: 13, 53
391 BTK 7件: NF-kappa B signaling pathway, Osteoclast differentiation, Platelet activation, B cell receptor signaling pathway, Fc epsilon RI signaling pathway, Epstein-Barr virus infection, Primary immunodeficiency D12467 Evobrutinib 3件: 13, 46, 49
392 THRA 2件: Neuroactive ligand-receptor interaction, Thyroid hormone signaling pathway D08128 Liothyronine 4件: 13, 78, 210, 212
393 THRB 2件: Neuroactive ligand-receptor interaction, Thyroid hormone signaling pathway D08128 Liothyronine 4件: 13, 78, 210, 212
394 TNF 67件: Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Apoptosis, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Asthma, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D01583 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228
395 TOP2A 1件: Platinum drug resistance D00125 Etoposide 10件: 13, 14, 26, 28, 34, 60, 65, 85, 164, 331
396 TOP2A 1件: Platinum drug resistance D03730 Dexrazoxane 1件: 13
397 TOP2A 1件: Platinum drug resistance D05522 Pixantrone 1件: 13
398 TOP2A 1件: Platinum drug resistance D08224 Mitoxantrone 1件: 13
399 TOP2B 1件: Platinum drug resistance D00125 Etoposide 10件: 13, 14, 26, 28, 34, 60, 65, 85, 164, 331
400 TOP2B 1件: Platinum drug resistance D03730 Dexrazoxane 1件: 13
401 TOP2B 1件: Platinum drug resistance D05522 Pixantrone 1件: 13
402 TOP2B 1件: Platinum drug resistance D08224 Mitoxantrone 1件: 13
403 C5 11件: Neuroactive ligand-receptor interaction, Complement and coagulation cascades, Neutrophil extracellular trap formation, Regulation of actin cytoskeleton, Alcoholic liver disease, Prion disease, Pertussis, Staphylococcus aureus infection, Herpes simplex virus 1 infection, Coronavirus disease - COVID-19, Systemic lupus erythematosus D03940 Eculizumab 7件: 11, 13, 14, 61, 62, 109, 222
404 C5 11件: Neuroactive ligand-receptor interaction, Complement and coagulation cascades, Neutrophil extracellular trap formation, Regulation of actin cytoskeleton, Alcoholic liver disease, Prion disease, Pertussis, Staphylococcus aureus infection, Herpes simplex virus 1 infection, Coronavirus disease - COVID-19, Systemic lupus erythematosus D11054 Ravulizumab 7件: 2, 11, 13, 50, 62, 66, 109
405 VDR 5件: Parathyroid hormone synthesis, secretion and action, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Tuberculosis, Chemical carcinogenesis - receptor activation D00188 Cholecalciferol 24件: 6, 13, 19, 20, 28, 34, 46, 49, 51, 53, 56, 60, 65, 84, 85, 96, 97, 98, 162, 202, 228, 271, 298, 299
406 VEGFA 24件: EGFR tyrosine kinase inhibitor resistance, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, HIF-1 signaling pathway, PI3K-Akt signaling pathway, VEGF signaling pathway, Focal adhesion, Relaxin signaling pathway, AGE-RAGE signaling pathway in diabetic complications, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Chemical carcinogenesis - reactive oxygen species, Renal cell carcinoma, Pancreatic cancer, Bladder cancer, Rheumatoid arthritis, Fluid shear stress and atherosclerosis D06409 Bevacizumab 6件: 13, 34, 85, 87, 227, 280
407 XDH 6件: Purine metabolism, Caffeine metabolism, Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Peroxisome D01206 Febuxostat 3件: 2, 6, 13
408 CA1 2件: Nitrogen metabolism, Metabolic pathways D00218 Acetazolamide 8件: 13, 86, 90, 115, 154, 155, 225, 230
409 CA2 7件: Nitrogen metabolism, Metabolic pathways, Proximal tubule bicarbonate reclamation, Collecting duct acid secretion, Gastric acid secretion, Pancreatic secretion, Bile secretion D00218 Acetazolamide 8件: 13, 86, 90, 115, 154, 155, 225, 230
410 CA3 2件: Nitrogen metabolism, Metabolic pathways D00218 Acetazolamide 8件: 13, 86, 90, 115, 154, 155, 225, 230
411 CA4 3件: Nitrogen metabolism, Metabolic pathways, Proximal tubule bicarbonate reclamation D00218 Acetazolamide 8件: 13, 86, 90, 115, 154, 155, 225, 230
412 CA5A 2件: Nitrogen metabolism, Metabolic pathways D00218 Acetazolamide 8件: 13, 86, 90, 115, 154, 155, 225, 230
413 CA6 2件: Nitrogen metabolism, Metabolic pathways D00218 Acetazolamide 8件: 13, 86, 90, 115, 154, 155, 225, 230
414 CA7 2件: Nitrogen metabolism, Metabolic pathways D00218 Acetazolamide 8件: 13, 86, 90, 115, 154, 155, 225, 230
415 CA8 2件: Nitrogen metabolism, Metabolic pathways D00218 Acetazolamide 8件: 13, 86, 90, 115, 154, 155, 225, 230
416 CA9 2件: Nitrogen metabolism, Metabolic pathways D00218 Acetazolamide 8件: 13, 86, 90, 115, 154, 155, 225, 230
417 CA12 2件: Nitrogen metabolism, Metabolic pathways D00218 Acetazolamide 8件: 13, 86, 90, 115, 154, 155, 225, 230
418 CACNA1C 34件: MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy D07450 Amlodipine 4件: 13, 51, 67, 298
419 CACNA1D 35件: MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cellular senescence, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Carbohydrate digestion and absorption, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy D07450 Amlodipine 4件: 13, 51, 67, 298
420 CACNA1F 27件: MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy D07450 Amlodipine 4件: 13, 51, 67, 298
421 CACNA1S 27件: MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy D07450 Amlodipine 4件: 13, 51, 67, 298
422 CACNA2D1 7件: MAPK signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Oxytocin signaling pathway, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy D00332 Gabapentin 5件: 6, 13, 19, 70, 298
423 CACNA2D1 7件: MAPK signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Oxytocin signaling pathway, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy D02716 Pregabalin 5件: 13, 36, 46, 70, 298
424 IL1R2 7件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Amoebiasis, Human T-cell leukemia virus 1 infection, Transcriptional misregulation in cancer, Prostate cancer, Fluid shear stress and atherosclerosis D02934 Anakinra 18件: 2, 13, 15, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299
425 VKORC1 3件: Ubiquinone and other terpenoid-quinone biosynthesis, Metabolic pathways, Biosynthesis of cofactors D08682 Warfarin 11件: 6, 8, 13, 19, 46, 49, 66, 85, 86, 88, 91
426 ALDH5A1 3件: Alanine, aspartate and glutamate metabolism, Butanoate metabolism, Metabolic pathways D00399 Valproic acid 14件: 2, 3, 5, 6, 13, 26, 65, 85, 90, 102, 127, 222, 233, 256
427 TAS1R2 2件: Taste transduction, Carbohydrate digestion and absorption D02381 Aspartame 4件: 6, 13, 67, 86
428 TAS1R3 2件: Taste transduction, Carbohydrate digestion and absorption D02381 Aspartame 4件: 6, 13, 67, 86
429 LINGO1 - D11767 Opicinumab 1件: 13
430 PDE5A 3件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway D08668 Vardenafil 3件: 13, 86, 299
431 S1PR4 3件: FoxO signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D10968 Ozanimod 3件: 13, 96, 97
432 TNFSF13 3件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, Rheumatoid arthritis D09704 Atacicept 4件: 13, 46, 49, 66
433 CACNA1I 7件: MAPK signaling pathway, Calcium signaling pathway, Circadian entrainment, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome D00399 Valproic acid 14件: 2, 3, 5, 6, 13, 26, 65, 85, 90, 102, 127, 222, 233, 256
434 CACNA1H 7件: MAPK signaling pathway, Calcium signaling pathway, Circadian entrainment, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome D00399 Valproic acid 14件: 2, 3, 5, 6, 13, 26, 65, 85, 90, 102, 127, 222, 233, 256
435 CACNA1G 8件: MAPK signaling pathway, Calcium signaling pathway, Circadian entrainment, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome D00399 Valproic acid 14件: 2, 3, 5, 6, 13, 26, 65, 85, 90, 102, 127, 222, 233, 256
436 CHRNA6 3件: Neuroactive ligand-receptor interaction, Cholinergic synapse, Nicotine addiction D03365 Nicotine 3件: 6, 13, 84
437 CACNA2D2 7件: MAPK signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Oxytocin signaling pathway, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy D00332 Gabapentin 5件: 6, 13, 19, 70, 298
438 CACNA2D2 7件: MAPK signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Oxytocin signaling pathway, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy D02716 Pregabalin 5件: 13, 36, 46, 70, 298
439 S1PR2 2件: Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D10968 Ozanimod 3件: 13, 96, 97
440 CD19 5件: PI3K-Akt signaling pathway, Hematopoietic cell lineage, B cell receptor signaling pathway, Epstein-Barr virus infection, Primary immunodeficiency D11757 Inebilizumab 4件: 11, 13, 51, 300
441 MS4A1 1件: Hematopoietic cell lineage D02994 Rituximab 47件: 13, 14, 19, 26, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 53, 55, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 162, 222, 229, 256, 271, 274, 283, 284, 285, 288, 296, 300, 331
442 MS4A1 1件: Hematopoietic cell lineage D05218 Ocrelizumab 3件: 13, 46, 49
443 MS4A1 1件: Hematopoietic cell lineage D09314 Ofatumumab 3件: 13, 35, 46
444 MS4A1 1件: Hematopoietic cell lineage D11243 Ublituximab 1件: 13
445 CACNA2D4 7件: MAPK signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Oxytocin signaling pathway, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy D00332 Gabapentin 5件: 6, 13, 19, 70, 298
446 CACNA2D4 7件: MAPK signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Oxytocin signaling pathway, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy D02716 Pregabalin 5件: 13, 36, 46, 70, 298
447 CD80 11件: Virion - Adenovirus, Cell adhesion molecules, Toll-like receptor signaling pathway, Intestinal immune network for IgA production, Type I diabetes mellitus, Autoimmune thyroid disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Viral myocarditis D03203 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300
448 CD86 13件: Virion - Adenovirus, Cell adhesion molecules, Toll-like receptor signaling pathway, Intestinal immune network for IgA production, Type I diabetes mellitus, Kaposi sarcoma-associated herpesvirus infection, Transcriptional misregulation in cancer, Autoimmune thyroid disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Viral myocarditis D03203 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300
449 CD38 7件: Nicotinate and nicotinamide metabolism, Metabolic pathways, Calcium signaling pathway, Hematopoietic cell lineage, Oxytocin signaling pathway, Salivary secretion, Pancreatic secretion D10777 Daratumumab 5件: 13, 28, 48, 49, 63
450 GABBR2 7件: cAMP signaling pathway, Neuroactive ligand-receptor interaction, GABAergic synapse, Taste transduction, Estrogen signaling pathway, GnRH secretion, Morphine addiction D00241 Baclofen 8件: 2, 10, 13, 18, 65, 70, 149, 206
451 GABBR2 7件: cAMP signaling pathway, Neuroactive ligand-receptor interaction, GABAergic synapse, Taste transduction, Estrogen signaling pathway, GnRH secretion, Morphine addiction D08861 Arbaclofen Placarbil 1件: 13
452 GABBR2 7件: cAMP signaling pathway, Neuroactive ligand-receptor interaction, GABAergic synapse, Taste transduction, Estrogen signaling pathway, GnRH secretion, Morphine addiction D09791 Arbaclofen 2件: 13, 206
453 KEAP1 6件: Ubiquitin mediated proteolysis, Parkinson disease, Pathways in cancer, Chemical carcinogenesis - reactive oxygen species, Hepatocellular carcinoma, Fluid shear stress and atherosclerosis D03846 Dimethyl fumarate 5件: 13, 49, 51, 86, 296
454 SV2A 1件: ECM-receptor interaction D00709 Levetiracetam 2件: 13, 307